Gerald L. Hogue is Director at POINT Biopharma Global Inc. (PNT). They have made 1 open-market trade across 1 company since 2022, most recently 2023-12-26.
CIK 0001868738
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $25K since 2022, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PNT | 21,596 | $270K |
Shares reported on the most recent Form 4, priced at the 2023-03-23 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PNT | BUY | 2022-11-25 | 2022-11-28 | $6.82 | $25K | +0.6% | +1.2% | +12.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.